MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2026.05.007

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2026

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.

Jirovec Elise, Jalkanen Katriina J, Quixabeira Dafne C A, Clubb James H A, Alanko Tuomo, Kudling Tatiana V, Arias Victor, Pakola Santeri A, Grönberg-Vähä-Koskela Susanna, van der Heijden Mirte, Färkkilä Anniina, Kononen Juha, Sormunen Jorma, Kemppainen Jukka, Hellesuo Maria, Haybout Lyna, Kistler Claudia, Sorsa Suvi, Havunen Riikka, Santos Joao M, Kanerva Anna, Cervera-Carrascon Victor, Hemminki Otto, Hemminki Akseli

СтатьяКлиническое исследование I фазыПеревод в очереди

Аннотация

TILT-123 (Ad5/3-E2F-d24-hTNFα-IRES-hIL2, igrelimogene litadenorepvec) is a chimeric oncolytic adenovirus engineered to selectively replicate in tumor cells and express tumor necrosis factor (TNF) and interleukin-2 (IL-2). While oncolytic viruses are commonly administered intratumorally, this approach often restricts practical applicability. Intravenous delivery is less invasive and offers a more practical alternative; however, systemic immune barriers challenge effective tumor targeting. In a cohort of a phase 1 clinical trial, six patients with advanced solid tumors who had exhausted standard treatments received two intravenous doses of TILT-123 (split-dose), per treatment day across seven cycles. Safety was the primary objective, while efficacy outcomes were exploratory and assessed using positron emission tomography/-computed tomography (PET/CT) imaging, along with overall survival. Split-dosing was safe, with chills, fever, fatigue, and lymphocyte reduction being the most common treatment-related events. In imaging, the disease control rate was 83.3% according to PET criteria and 33.3% by RECIST 1.1. The median overall survival was 198 days. Split-dosing increased the area under the curve of TILT-123 and amplified systemic cytokine responses. Proteomic analysis of serum and neutralizing antibody profiling indicated that enhanced humoral immune activity was associated with shorter overall survival. Post-treatment biopsies confirmed virus presence and alterations in immune cell composition. These findings support further evaluation of intravenous TILT-123 administration in clinical trials.

Для цитирования: Jirovec Elise, Jalkanen Katriina J, Quixabeira Dafne C A, Clubb James H A, Alanko Tuomo, Kudling Tatiana V, Arias Victor, Pakola Santeri A, Grönberg-Vähä-Koskela Susanna, van der Heijden Mirte, Färkkilä Anniina, Kononen Juha, Sormunen Jorma, Kemppainen Jukka, Hellesuo Maria, Haybout Lyna, Kistler Claudia, Sorsa Suvi, Havunen Riikka, Santos Joao M, Kanerva Anna, Cervera-Carrascon Victor, Hemminki Otto, Hemminki Akseli. Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.. Molecular therapy : the journal of the American Society of Gene Therapy. 2026. DOI: 10.1016/j.ymthe.2026.05.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.